Study #2017-0141
AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-933-2658
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.